

Special Issue

Research Advances and Therapeutic Strategies (RATS) in Cardio-Oncology

Message from the Guest Editors

Advances in oncology have improved cancer survivorship; however, they have also revealed a spectrum of treatment-related cardiovascular complications—from anthracycline-induced cardiomyopathy and radiation-mediated vascular injury to immune checkpoint inhibitor myocarditis and targeted-therapy arrhythmias. Emerging research has uncovered the mechanisms driving these toxicities, including oxidative stress, endothelial dysfunction, immune dysregulation, and genetic susceptibility. We invite submissions encompassing studies that elucidate the molecular and genetic drivers of therapy-related cardiotoxicity; investigations that validate advanced imaging modalities, circulating biomarkers, digital health platforms, and AI-driven tools for early detection and seamless collaboration between oncology and cardiology teams; evaluations of novel cardioprotective strategies—whether pharmacologic, lifestyle-based, or device-oriented; the development of practical risk stratification frameworks and implementable care pathways tailored to oncology populations; and analyses that address health disparities and real-world cardiovascular outcomes across diverse cancer survivor cohorts.

Guest Editors

Dr. Avirup Guha
Dr. Viraj Shah
Dr. Tarek Nahle

Deadline for manuscript submissions

closed (1 May 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/246818

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)